HLS Therapeutics Inc. Stock price

Equities

HLS

CA40390B1094

Pharmaceuticals

Market Closed - Toronto S.E. 14:50:27 2024-03-01 EST 5-day change 1st Jan Change
4.2 CAD +0.48% Intraday chart for HLS Therapeutics Inc. +5.53% +6.33%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Enjoy this offer
* See conditions on site
Sales 2023 * 63.2M 85.68M Sales 2024 * 66.3M 89.88M Capitalization 99.01M 134M
Net income 2023 * -26M -35.25M Net income 2024 * -8M -10.85M EV / Sales 2023 * 1.57 x
Net cash position 2023 * - 0 Net cash position 2024 * - 0 EV / Sales 2024 * 1.49 x
P/E ratio 2023 *
-3.97 x
P/E ratio 2024 *
-14.1 x
Employees 99
Yield 2023 *
4.68%
Yield 2024 *
-
Free-Float 97.21%
More Fundamentals * Assessed data
Dynamic Chart
HLS Therapeutics Says Vascepa Now Reimbursed by British Columbia's Provincial Drug Plan MT
HLS Therapeutics Brief: Announcing that Vascepa is now reimbursed by British Columbia's Provincial Drug Plan MT
HLS Therapeutics Inc. Announces CFO Changes CI
HLS Therapeutics Announcing CFO Departure; John Hanna appointed Interim CFO to replace departing CFO Tim Hendrickson MT
HLS Therapeutics Brief: Announcing CFO Departure; John Hanna appointed Interim CFO to replace departing CFO Tim Hendrickson MT
HLS Therapeutics Brief: Adds Analysis Also Found Icosapent Ethyl Was Associated with a 41% Reduction in Total Events Compared with Placebo MT
HLS Therapeutics Brief: Says New REDUCE-IT Analyses Show Vascepa (Icosapent Ethyl) Associated with 29% Relative Risk Reduction Vs Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline MT
HLS Therapeutics Inc. Announces Results from New REDUCE-IT Analyses CI
HLS Therapeutics Inc.'s Equity Buyback announced on November 10, 2022, has expired. CI
HLS Therapeutics Downgraded to Hold at Stifel GMP on Revenue Concerns; Price Target Cut to C$5.00 MT
HLS Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Tranche Update on HLS Therapeutics Inc.'s Equity Buyback Plan announced on November 10, 2022. CI
HLS Therapeutics Inc. announces an Equity Buyback for 1,607,892 shares, representing 5% of its issued share capital. CI
Transcript : HLS Therapeutics Inc., Q3 2023 Earnings Call, Nov 09, 2023
HLS Therapeutics Reports Q3 2023 Revenue of US$16.0 Million, Renews Normal Course Issuer Bid MT
More news
1 day+0.48%
1 week+5.53%
Current month+0.48%
1 month+1.20%
3 months+22.09%
6 months-10.06%
Current year+6.33%
More quotes
1 week
3.68
Extreme 3.68
4.24
1 month
3.68
Extreme 3.68
4.28
Current year
3.68
Extreme 3.68
4.47
1 year
3.34
Extreme 3.34
9.50
3 years
3.34
Extreme 3.34
21.76
5 years
3.34
Extreme 3.34
25.92
10 years
3.34
Extreme 3.34
25.92
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 23-04-30
Director of Finance/CFO - 23-06-21
Compliance Officer 43 18-05-06
Members of the board TitleAgeSince
Chairman 46 21-06-17
Director/Board Member 66 19-03-20
Director of Finance/CFO - 23-06-21
More insiders
Date Price Change Volume
24-03-01 4.2 +0.48% 900
24-02-29 4.18 +4.50% 13,700
24-02-28 4 +0.50% 2,656
24-02-27 3.98 +5.29% 9,297
24-02-26 3.78 -5.03% 3,500

Delayed Quote Toronto S.E., March 01, 2024 at 02:50 pm

More quotes
HLS Therapeutics Inc. is a pharmaceutical company. It is focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. It is also focused on products targeting the central nervous system and cardiovascular therapeutic areas. Its products include Clozaril, CSAN Pronto, MyCare Insite, MyCare Psychiatry, PERSERIS, Trinomia and Vascepa. Its lead product is Clozaril, which is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Trinomia product related to the treatment of cardiovascular disease.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
3.097 USD
Average target price
5.17 USD
Spread / Average Target
+66.92%
Consensus
  1. Stock
  2. Equities
  3. Stock HLS Therapeutics Inc. - Toronto S.E.
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW